In the last 25 years we have gone from studying single genes to entire genomes. It's amazing that we already have the genome sequences of 599 viruses and viroids, 205 naturally occurring plasmids, 185 organelles, 31 eubacteria, seven archaea, one fungus, one plant, and two mammals. Due to the public availability of the human genome, at least 30 disease genes have been positionaly cloned. 1 There have indeed been many impressive advances in the fields of genomics, [1] [2] [3] [4] [5] but along with these fetes the HGP has also catalysed the need for post-gen- 6 domain-fusion analysis 6,7 and expression correlation. 6 From Sali 13 and Doolittle.
14 omic technologies. The post-genomics era is spawning and proteomics is set to play a major role in defining biological systems at a molecular level.
Here we look at large-scale proteomics in the post-genome era and reflect on its future impact to study biological systems in medical research. The field of proteomics transcends genomics as it aims to convert raw gene sequence data, and measurement of gene expression, to information describing the actions of those proteins controlling biological systems. The public International Human Genome Sequencing Consortium estimates that there are 31 000 proteinencoding genes in the human genome, of which they can now provide a list of 22 000; Celera finds about 26 000-thus only about 1.1-1.4% of the Genome actually encodes protein. 1 This number of coding genes in the human sequence compares with 6000 for a yeast cell, 13 000 for a fly, 18 000 for a worm and 26 000 for a plant. Furthermore, only 94 of 1278 protein families in our genome appear to be specific to vertebrates and these cover elementary cellular functions such as metabolism or protein expression (ie transcription of DNA into RNA, and translation of RNA into protein). It is remarkable that the biggest difference between humans, worms or flies is the complexity of our proteins: more domains (modules) per protein and attendant novel combinations resulting from alternate assemblies of these modules. 6 Two groups have attempted to order this complexity by developing computational methods that associate proteins that are functionally linked through a metabolic pathway or structural complex. 6, 7 Importantly, these approaches do not rely on direct sequence similarity, rather they group proteins that are part of the same pathway or assembly ( Figure 1 ) and define them as being 'functionally linked'. While these, and other software tools will continue to play a pivotal role in our understand-
The Pharmacogenomics Journal ing and representation of biological systems, critical information needed to construct useful models of pathways and assemblies is only gained through experimental proteomics data. The size and complexity of the task can be appreciated by assuming between one and ten functional links per protein that results in 6000-60 000 links for a single yeast cell and a rapid temporal and spatial propagation of interactions in protein cascades and networks. The need to assign function, characterize this molecular interplay and ultimately define cellular and organismal properties in the context of a biological system will require a combination of computational methods and highthroughput proteomics.
The concept of genome-wide protein profiling is 20 years old, but has become a reality only recently through Table 1 Protein analysis technologies and their applications in large-scale proteomics. While enzymatic activity, receptor ligand, cytokine assays, biosensor, etc are integral to proteomics, they have not been included in the table due to their relative low-speed screening current sequence databases and technically impressive advances with the integration of powerful analytical tools, ranging from two-dimensional electrophoresis (2-DE) combined with mass spectrometry (MS), yeast twohybrid system, to protein chips containing protein and peptide libraries, coupled with high-throughput functional screening assays. Currently, however, there is much investment in measurement of mRNA expression. It is highly unlikely that there exists a simple unidirectional or linear relationship between the transcriptome and proteome: the two data sets are distinctly different and both have idiosyncratic control and regulation over biological effects. We see at least three reasons to perform both measurements. Firstly, temporal and spatial expression of proteins is not apparent from gene expression analysis. Secondly, post-translational modiwww.nature.com/tpj fications (PTMs), static and dynamic, are rich in variety (more than 200 documented 8 ) and typically not apparent from primary sequence data. Furthermore, even with the knowledge of a consensus sequence there are currently no general rules describing when and where phosphorylation, or other PTMs, takes place and how this functionally affects a biological system. Thirdly, and perhaps most importantly, inducible protein-ligand interactions cannot be measured by transcriptomics. A comprehensive approach to measuring expression profiles and interactions of biological systems is therefore warranted (Figure 2 ). Both transcriptomics and proteomics must be used for our measurements, and we must now equally invest in proteome directed research. In the immediate future these large-scale molecular screening methods will contribute in areas such as accelerated and accurate diagnosis of patients and further classification of diseases such as tumours so that timely treatment definition or selection can be realised.
In asking how proteomics will impact on medicine, we should start by asking what can it enable now. A description of technologies (Table 1) and their applications reveals that we already have a huge variety of technologies allowing the global analysis of systems. Central to most screening techniques lies the mass spectrometer as it enables outstanding speed and accuracy in protein identification. Large-scale proteomics is and will be used for three distinct applications: 
Cell map proteomics aims at measuring the subcellular protein content by the purification of organelles and their protein complexes followed by mass-spectrometric identification of the components. Systematic identification of subcellular protein content allows a refined display and categorisation of the cellular processes based on location. Applications are similar to those pointed out above.
Modular proteomics aims to rationalise how biological systems are built up. To fully understand biological systems we believe that protein function cannot easily be predicted from studying singular components. Instead cellular functions are carried out by 'modules' made up of many species of interacting molecules. These functional modules exist as a critical level of biological organisation.
12 Proteomics must aim to generate data in the form of discrete functional modules based on interacting proteins. Accordingly proteomics should attempt to validate functional modules by classifying and cataloguing those proteins that contribute to the functional process in question. The data measurements will be used in conjunction with sophisticated algorithms described above 6, 7 which in turn will lead to the elucidation of common biological 'network architectures'. Higher-level properties of cells, such as the ability to integrate information from multiple sources, will be described by a pattern of connections
The Pharmacogenomics Journal amongst the functional modules. General (affinity-based) approaches that can simplify protein mixtures and link related protein-protein and protein-DNA interactions are set to make massive in roads for high-throughput modular protein analysis.
What are the potential impacts of proteomics on medicine? The potentials are huge, but these must be tempered by the current practical technical issues. Ultimately, protein profiles should be able to provide qualitative and quantitative read-outs of patient serum proteins that reflect a given disease state or a response to disease treatment. Comprehensive qualitatative and quantitative protein analyses may replace current diagnostic laboratory technologies. Proteomics may provide prognostic data that reflect tumour behaviour in a fashion that incorporates both intrinsic tumour characteristics as well as host-response factors. On a more immediate front, proteomics will identify common pathways of drug action that indicate side-effect profiles, synergistic and antagonistic interactions, drug-resistance, and drug efficacy before entering into expensive and time-dependent clinical trials. Ahead lies a road of limitations and opportunities. Despite the power of proteomic techniques several limitations remain both in theory and in practice. Some key issues are for instance, in humans, proteins have a dynamic range of expression of more than six orders of magnitude rendering simultaneous analysis of all system components extremely difficult. There is yet no known amplification of proteins that is generally applicable. The analysis of most PTMs is essentially not solved but needs to be addressed so that we can more expansively analyse biological systems. The differential solubility of proteins poses a problem for all areas of proteomics. These limitations of the technology are actively being addressed.
New methods enabling the simplification and quantitation of large protein mixtures are currently being developed, 11 as well as exciting developments in bioinformatics. 6, 7 Initially proteomics will be used for drug development; where combined with current genomic screening techniques, such as differential display-PCR, cDNA micro arrays, and serial analysis of gene expression (SAGE), it should make drugs better, safer and more efficacious. In the long term, we anticipate the ability to dissect biological systems through robust extraction procedures where one can study functional modules. This requires only to look at a small subset of proteins from a complete mixture, and herein lies one challenge: to screen a particular constellation of proteins that are critical to a biological process. As David Baltimore recently wrote: 'Celera's achievement of producing a draft sequence in only a year of data-gathering is a testament to what can be realized today with the new capillary sequencers, sufficient computing power and the faith of investors.' With a little 'faith' the timing looks right for proteomics to make its impact.
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INTRODUCTION
Pharmacogenetic differences can be 10-to more than 40-fold between individuals within an 'ethnic' group, while the mean variation between ethnic groups is rarely more than 2-to 3-fold. This observation is the hallmark of complex (or, multifactorial) traits, ie contribution of multiple genes and environmental factors on these genes. The concept now emerging is that the total number of alleles encoding all the features related to 'categorization of race or ethnic group' (skin color, hair color and texture, facial traits) will probably be quite small (eg in the dozens), compared with the number of alleles that encode interindividual differences even within the same ethnic group; the same is predicted to be true for alleles that govern variation in blood pressure, ability to taste, capacity to metabolize drugs, etc. Because of considerable genetic admixture in most human populations, federal governments must rethink their mandates that minorities and ethnic groups be included for political reasons as 'distinct groups'-in each and every clinical study. The idea of grouping by ethnicity certainly has its advantages in studies of traits that are predominantly expressed in specific populations, and may not be an unwarranted starting point in such population-based studies. The most successful approach to search for allelic effects is therefore likely to require judicious choice of study populations, based on the knowledge of the trait being studied-in some cases a relatively unadmixed population, in other cases a diverse, more admixed population. In designing pharmacogenomic studies, it is therefore imperative for the clinical researcher to be aware and appreciate the richness and diversity of alleles that exist (but to very differing degrees) in each racial and ethnic group, rather than to study such groups with the idea that they are genetically 'pure.' Adverse drug reactions, due in large part to interindividual variability in drug response, ranks between the fourth and sixth leading cause of death in the US. 1 Pharmacogenetics and pharmacogenomics represent 'the studies of variability in drug response due to heredity.' Pharmacogenetic advances, which have exploded during the past decade due to our rapidly increasing knowledge of the human genome, should help in the substantial reduction of drug-caused morbidity and mortality. In a recent listing of many dozens of pharmacogenetic differences, 2 the majority of the diversity occurs in drug metabolism genes, with some present in drug receptor and transporter genes, and many others not yet explained on a molecular basis. In principle, a pharmacogenetic disorder might reflect allelic differences in any 'susceptibility gene. ' If one considers that a drug (or other environmental chemical, metabolite, or heavy metal) may theoretically act as an agonist or antagonist (or activator or inhibitor) of virtually any gene product (target) in the cell, then it is likely that most-if not every-gene in the human genome might be considered either directly or indirectly to be a susceptibility gene.
3 Pharmacogenetic differences are often 10-fold to more than 40-fold between the highest and lowest individual in any given population, 2 yet the mean difference between any two ethnic populations is rarely greater than 2-or 3-fold. 4 The fact-that interindividual variance is much greater than group variation-is a hallmark of complex traits and is the subject of this invited 'Perspectives' article.
RACE AND ETHNICITY
The term 'race' is derived from Latingeneratio (n) and generare (v)-meaning 'generation' and 'to engender', respectively. Webster's Dictionary defines race as 'any of the different varieties of mankind, mainly the Caucasoid, Mongoloid, and Negroid groups, distinguished by color of skin and type of hair.' Also, 'any geographical, national, or tribal ethnic grouping.' Some anthropologists regard Arabs, Jews, Latinos and Spaniards as 'distinct races', whereas most would prefer to call these 'ethnic groups.' Most regard the origin of human races similar to that of animal or plant spec-
